Results 1 to 10 of about 221,455 (333)

IgG4-to-IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4-Related Disease. [PDF]

ACR Open Rheumatol
Cho YM, Quinteros A, Khattar P, Edelman MC, El Khoury L, Marder G.   +5 more
europepmc   +1 more source

Use of Rituximab in a Sjogren's Disease-Associated Inflammatory Pseudotumor: A Case Report. [PDF]

Case Rep Rheumatol
Shing V, Wesselius L, Stanton M, Beamer S, Rath T, Nagaraja V.   +5 more
europepmc   +1 more source

Real‑world pharmacovigilance of rituximab‑associated adverse reactions in children and adolescents: Disproportionality signal detection and time‑to‑onset pattern characterization using the FAERS database. [PDF]

Hum Vaccin Immunother
Fang W, Liu B, Cai L.
europepmc   +1 more source

ABCD-Trial: study protocol for a randomized, double-blind, placebo-controlled study in patients with Amyotrophic lateral sclerosis for the evaluation of efficacy and safety of B-Cell Depletion with rituximab (ABCD). [PDF]

Trials
Ufer F, Rössling R, Spottke A, Németh R, Schaprian T, Coninck NK, Gamez A, Sterl R, Naumann P, Behr N, Maier A, Meyer T, Weydt P, Prüss H.   +13 more
europepmc   +1 more source

A comparative analysis of semiannual versus annual rituximab maintenance in patients with refractory idiopathic inflammatory myopathies: a retrospective longitudinal real-world study. [PDF]

Rev Assoc Med Bras (1992)
Serrano RL, Souza FHC, Miossi R, Faria MSMS, Shinjo SK.   +4 more
europepmc   +1 more source

Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis.

JAMA Neurol
Kallin S, Svenningsson A, Olén O, Hedin C, Lycke J, Alping P.   +5 more
europepmc   +1 more source

Subcutaneous versus intravenous ultra-low-dose rituximab in rheumatoid arthritis: a randomized controlled PK-PD non-inferiority trial. [PDF]

Rheumatology (Oxford)
Bovens PMET, van der Togt CJT, den Broeder N, Verhoef LM, van der Maas A, Hobo W, Bloem K, Ter Heine R, van den Bemt BJF, den Broeder AA.   +9 more
europepmc   +1 more source

Rituximab in Mucous Membrane Pemphigoid: Current Evidence and Clinical Perspectives. [PDF]

Healthcare (Basel)
Popa LG, Giurcaneanu C, Coviltir V, Popescu C, Ali S, Cozma M, Orzan OA.   +6 more
europepmc   +1 more source

Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review. [PDF]

Front Pharmacol
Halkidis K, Meng C, Snyder J.
europepmc   +1 more source

Longitudinal Anti-HBs Monitoring and Seroprotection Patterns in Rituximab-Treated Patients with Pemphigus Vulgaris: A Retrospective Cohort Study. [PDF]

Diagnostics (Basel)
Ecer N, Harman M.
europepmc   +1 more source